G
o
o
g
l
e
×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
ImmunityBio shares target raised by Piper Sandler on potential approval By Investing.com
Investing.com
On Monday, Piper Sandler adjusted its price target for ImmunityBio Inc (NASDAQ:IBRX), increasing it to $5.00 from the previous $4.00,...
3 days ago
ImmunityBio inoculates itself against financial pain, inking $210M royalty deal to get cancer drug to market
Fierce Biotech
ImmunityBio inoculates itself against financial pain, inking $210M royalty deal to get cancer drug to market ... ImmunityBio has traded future...
2 months ago
Is Immunitybio Inc (IBRX) Stock a Smart Value?
InvestorsObserver
Immunitybio Inc (IBRX) stock has gained 207.60% over the last 12 months, and the average rating from Wall Street analysts is a Buy.
2 days ago
ImmunityBio Gets $320M Investment
Los Angeles Business Journal
ImmunityBio Gets $320M Investment ... Culver City-based immunotherapy company ImmunityBio Inc. has received as much as $320 million in financing...
2 months ago
ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?
Yahoo Finance
According to some industry analysts covering ImmunityBio, breakeven is near. They expect the company to post a final loss in 2025, before...
1 month ago
iBio, ImmunityBio, Mesoblast among healthcare movers
Seeking Alpha
Read about the top stock gainers and losers in the pharmaceutical, biotechnology, and healthcare sectors, along with updates on related...
1 day ago
IBRX 6-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages ImmunityBio (IBRX) Investors ...
WBOY.com
SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2023 / Hagens Berman urges ImmunityBio, Inc. (NASDAQ:IBRX) investors who suffered substantial losses to submit...
1 day ago
ImmunityBio Snags $320M Royalty Deal Ahead of FDA Decision in April
BioSpace
Trading cash for single-digit royalties on products, the deal provides ImmunityBio with the cash it'll need to potentially commercialize its...
2 months ago
ImmunityBio inks $320m deal to advance bladder cancer drug and boost pipeline
Pharmaceutical Technology
ImmunityBio inks $320m deal to advance bladder cancer drug and boost pipeline. The deal will see ImmunityBio receiving an upfront $210m...
2 months ago
Piper Sandler Raises ImmunityBio (NASDAQ:IBRX) Price Target to $5.00
MarketBeat
Piper Sandler lifted their price target on ImmunityBio from $4.00 to $5.00 and gave the company a "neutral" rating in a research report on...
2 days ago